124 related articles for article (PubMed ID: 33648413)
21. Absence of class II-associated invariant chain peptide on leukemic blasts of patients promotes activation of autologous leukemia-reactive CD4+ T cells.
van Luijn MM; van den Ancker W; Chamuleau ME; Zevenbergen A; Westers TM; Ossenkoppele GJ; van Ham SM; van de Loosdrecht AA
Cancer Res; 2011 Apr; 71(7):2507-17. PubMed ID: 21310823
[TBL] [Abstract][Full Text] [Related]
22. Differential presentation of HLA-DR, DQ, and DP restriction elements by interferon-gamma-treated dermal fibroblasts.
Maurer DH; Hanke JH; Mickelson E; Rich RR; Pollack MS
J Immunol; 1987 Aug; 139(3):715-23. PubMed ID: 3110281
[TBL] [Abstract][Full Text] [Related]
23. Increased Levels of Circulating Monocytic- and Early-Stage Myeloid-Derived Suppressor Cells (MDSC) in Acute Myeloid Leukemia.
Lv J; Zhao Y; Zong H; Ma G; Wei X; Zhao Y
Clin Lab; 2021 Mar; 67(3):. PubMed ID: 33739029
[TBL] [Abstract][Full Text] [Related]
24. HLA class II allele and haplotype frequencies in iranian patients with acute myelogenous leukemia and control group.
Sarafnejad A; Khosravi F; Alimoghadam K; Dianat S; Ansaripour B; Moradi B; Dorkhosh S; Amirzargar A
Iran J Allergy Asthma Immunol; 2006 Sep; 5(3):115-9. PubMed ID: 17237562
[TBL] [Abstract][Full Text] [Related]
25. Most acute myeloid leukemia progenitor cells with long-term proliferative ability in vitro and in vivo have the phenotype CD34(+)/CD71(-)/HLA-DR-.
Blair A; Hogge DE; Sutherland HJ
Blood; 1998 Dec; 92(11):4325-35. PubMed ID: 9834239
[TBL] [Abstract][Full Text] [Related]
26. [Clinical analysis of HLA-DR-negative non-M3 AML].
Mori H; Sakai H; Sanada M; Shimamoto K; Sasaki S; Azuma R; Higuchi T; Harada H; Niikura H; Omine M; Fujita K; Takahashi N
Rinsho Ketsueki; 2007 Jul; 48(7):547-53. PubMed ID: 17695303
[TBL] [Abstract][Full Text] [Related]
27. HLA Evolutionary Divergence as a Prognostic Marker for AML Patients Undergoing Allogeneic Stem Cell Transplantation.
Roerden M; Nelde A; Heitmann JS; Klein R; Rammensee HG; Bethge WA; Walz JS
Cancers (Basel); 2020 Jul; 12(7):. PubMed ID: 32650450
[TBL] [Abstract][Full Text] [Related]
28. The prognostic value of CD2, CD4, and HLA-DR expression and FLT3-ITD mutation in adult acute promyelocytic leukemia.
Nie L; Ma R; Yuan X; Jiang L; Yang S; Xu H; Liu X; Liu Y; Zhang L; Zhu Z
Leuk Lymphoma; 2020 Oct; 61(10):2482-2487. PubMed ID: 32476519
[TBL] [Abstract][Full Text] [Related]
29. Mapping the HLA ligandome landscape of acute myeloid leukemia: a targeted approach toward peptide-based immunotherapy.
Berlin C; Kowalewski DJ; Schuster H; Mirza N; Walz S; Handel M; Schmid-Horch B; Salih HR; Kanz L; Rammensee HG; Stevanović S; Stickel JS
Leukemia; 2015 Mar; 29(3):647-59. PubMed ID: 25092142
[TBL] [Abstract][Full Text] [Related]
30. CD9 Is a Very Helpful Marker for Discriminating AML-M3 from HLA-DR-Negative Non-M3 AML.
Satlsar ES; Mosleh M; Mehrpouri M
Turk J Haematol; 2020 Nov; 37(4):287-289. PubMed ID: 32517420
[No Abstract] [Full Text] [Related]
31. Induction of death (CD95/FAS), activation and adhesion (CD54) molecules on blast cells of acute myelogenous leukemias by TNF-alpha and IFN-gamma.
Munker R; Andreeff M
Cytokines Mol Ther; 1996 Sep; 2(3):147-59. PubMed ID: 9384699
[TBL] [Abstract][Full Text] [Related]
32. Impaired antigen-presenting capability of monocytes correlated with their decreased expression of HLA-II antigens in patients with myeloid leukemia.
Gong FL; Feng XW; Grosse-Wilde H
J Tongji Med Univ; 1993; 13(2):65-70. PubMed ID: 8230358
[TBL] [Abstract][Full Text] [Related]
33. Flow cytometric analysis of acute leukemias. Diagnostic utility and critical analysis of data.
Kaleem Z; Crawford E; Pathan MH; Jasper L; Covinsky MA; Johnson LR; White G
Arch Pathol Lab Med; 2003 Jan; 127(1):42-8. PubMed ID: 12521365
[TBL] [Abstract][Full Text] [Related]
34. Mass spectrometry-assisted identification of ADAMTS13-derived peptides presented on HLA-DR and HLA-DQ.
Hrdinová J; Verbij FC; Kaijen PHP; Hartholt RB; van Alphen F; Lardy N; Ten Brinke A; Vanhoorelbeke K; Hindocha PJ; De Groot AS; Meijer AB; Voorberg J; Peyron I
Haematologica; 2018 Jun; 103(6):1083-1092. PubMed ID: 29567779
[TBL] [Abstract][Full Text] [Related]
35. Expression patterns of costimulatory molecules on cells derived from human hematological malignancies.
Zheng Z; Takahashi M; Aoki S; Toba K; Liu A; Osman Y; Takahashi H; Tsukada N; Suzuki N; Nikkuni K; Furukawa T; Koike T; Aizawa Y
J Exp Clin Cancer Res; 1998 Sep; 17(3):251-8. PubMed ID: 9894758
[TBL] [Abstract][Full Text] [Related]
36. HLA-G expression is irrelevant to prognosis in patients with acute myeloid leukemia.
Guo QY; Chen BG; Ruan YY; Lin A; Yan WH
Leuk Res; 2011 Oct; 35(10):1350-4. PubMed ID: 21696824
[TBL] [Abstract][Full Text] [Related]
37. NPM1-mutated acute myeloid leukemia of monocytic or myeloid origin exhibit distinct immunophenotypes.
Liu YR; Zhu HH; Ruan GR; Qin YZ; Shi HX; Lai YY; Chang Y; Wang YZ; Lu D; Hao L; Li JL; Li LD; Jiang B; Huang XJ
Leuk Res; 2013 Jul; 37(7):737-41. PubMed ID: 23601747
[TBL] [Abstract][Full Text] [Related]
38. Differential distribution of HLA-DQ beta/DR beta epitopes in the two forms of Guillain-Barré syndrome, acute motor axonal neuropathy and acute inflammatory demyelinating polyneuropathy (AIDP): identification of DQ beta epitopes associated with susceptibility to and protection from AIDP.
Magira EE; Papaioakim M; Nachamkin I; Asbury AK; Li CY; Ho TW; Griffin JW; McKhann GM; Monos DS
J Immunol; 2003 Mar; 170(6):3074-80. PubMed ID: 12626563
[TBL] [Abstract][Full Text] [Related]
39. Clonal evolution including partial loss of human leukocyte antigen genes favoring extramedullary acute myeloid leukemia relapse after matched related allogeneic hematopoietic stem cell transplantation.
Stölzel F; Hackmann K; Kuithan F; Mohr B; Füssel M; Oelschlägel U; Thiede C; Röllig C; Platzbecker U; Schetelig J; Illmer T; Schaich M; Seliger B; Hartmann A; Baretton G; Zietz C; Ehninger G; Schrock E; Bornhäuser M
Transplantation; 2012 Apr; 93(7):744-9. PubMed ID: 22314337
[TBL] [Abstract][Full Text] [Related]
40. Class II HLA Genotype Association With First-Phase Insulin Response Is Explained by Islet Autoantibodies.
Koskinen MK; Lempainen J; Löyttyniemi E; Helminen O; Hekkala A; Härkönen T; Kiviniemi M; Simell O; Knip M; Ilonen J; Toppari J; Veijola R
J Clin Endocrinol Metab; 2018 Aug; 103(8):2870-2878. PubMed ID: 29300921
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
